Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VKTX with free AI briefings, catalyst countdowns, and dilution alerts.

VKTX · Viking Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$959.8M Cash on Hand
21.9mo Cash Runway
25.1% Short Interest
$92.72 Analyst Target (18)
Follow VKTX by email Get an email when VKTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VKTX, unsubscribe in one click. Privacy

📣 What VKTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
VK2735 Weight Loss Phase 3 · NCT07104500 Active not recruiting
VK2809 NASH - Nonalcoholic Steatohepatitis Phase 2 · NCT04173065 Completed
VK5211 Hip Fractures Phase 2 · NCT02578095 Completed
SC VK3019 Obese Adults Phase 1 · NCT07846033 Recruiting
VK0214 Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy… Phase 1 · NCT04973657 Completed
VK2735 Drug Obese Adults Phase 1 · NCT07838740 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VKTX holds $959.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $131.7M/quarter from operations, an estimated runway of 21.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VKTX files for a raise →

👥 Who Owns VKTX

Insiders 2.7% Institutions (576 holders) 60.7% Public and other holders 36.6%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 9,539,067 7.48% 2026-09-30
Blackrock Inc. Institution (13F) 6,611,874 5.18% 2025-12-31
Vanguard Capital Management Institution (13G, 5%+) 5,877,263 4.61% 2026-03-31
State Street Corporation Institution (13F) 4,445,430 3.49% 2025-12-31
Morgan Stanley Institution (13F) 3,076,270 2.41% 2025-12-31
Brian Lian
President & CEO, Director · +254,600 options
Insider 2,572,441 2.02% 2026-07-28
Two Sigma Investments, LP Institution (13F) 2,435,737 1.91% 2025-12-31
Two Sigma Advisers, LP Institution (13F) 2,129,228 1.67% 2025-12-31
Geode Capital Management, LLC Institution (13F) 1,994,509 1.56% 2025-12-31
Citadel Advisors Llc Institution (13F) 1,732,421 1.36% 2025-12-31
Shaw D.E. & Co., Inc. Institution (13F) 1,718,493 1.35% 2025-12-31
Marianna Mancini
Chief Operating Officer · +128,200 options
Insider 422,760 0.33% 2026-07-28

Share count 127,522,189 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-01
filed 2026-08-07
Kelly-Gemmell Dorothy Elizabeth
Award (A) 6,333 – 6,333
2026-08-01
filed 2026-08-07
Kelly-Gemmell Dorothy Elizabeth
Option award (A) 40,800 – –
2026-07-29
filed 2026-07-29
Lian Brian
Sale (S) 148,517 $33.32 2,572,441
2026-07-29
filed 2026-07-29
Mancini Marianna
Sale (S) 18,217 $33.47 422,760
2026-07-29
filed 2026-07-29
ZANTE GREG
Sale (S) 21,217 $33.47 212,204

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full VKTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VKTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.